B.R.A.I.N. Biotechnology Research And Information Network AG: NatLifE 2020 Strategic Alliance Given Go-Ahead After Successful Interim Review
01 March 2016 12:10
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/Alliance
2016-03-01 / 12:10
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
NatLifE 2020 Strategic Alliance Given Go-Ahead After Successful Interim
Review
Alliance's second phase scheduled to commence as planned
Zwingenberg, March 01, 2016 - The NatLifE 2020 strategic alliance,
coordinated by BRAIN AG, was the first research alliance funded under the
German Ministry of Education and Research's (BMBF) "Innovation Initiative
for Industrial Biotechnology" programme, starting on February 01, 2013. In
the end of the year 2015 the alliance underwent an interim review by a
panel of scientific experts set up by the BMBF. The expert panel
recommended to enter into Phase 2 of the strategic alliance. The NatLifE
2020 alliance partners aim at developing a new generation of sustainably
produced and biologically active components, which may be used as active
ingredients by the cosmetics and food industries, which in turn will
notably improve the nutrition, health, well being and lives of people.
The first NatLifE 2020 phase saw the publication of eight scientific
papers, numerous lectures at symposia (25) as well as some initial patent
applications (six plus three in the pipeline), which all highlight the
extraordinary quality of what has been achieved so far in both the
scientific and economic arenas. During the upcoming NatLifE stages the
bioactive ingredients identified so far will now be fine-tuned with the
full value chain in mind. First positive taste and application experiments
involving some of the identified bioactive substances have already taken
place
"Phase 1 results have exceeded our expectations as coordinator in many
respects. After such a short period of research it is really impressive to
see how very promising some first bioactive substances perform in
application tests," says Dr. Michael Krohn, Unit Head BioActives &
Performance Proteins at BRAIN AG.
"For the upcoming second phase of the NatLifE 2020 programme, the 22
members of the alliance, among them AB Enzymes and AnalytiCon Discovery,
now include a larger number of industrial partners," explains Dr. Dirk
Sombroek, coordinator of the alliance's efforts and platform coordinator at
BRAIN AG. "We welcome Henkel AG & Co. KGaA as well as Phyton Biotech GmbH
as our new partners. We expect them to help the alliance exploit as of yet
untapped potential for synergies, in particular as regards market approval
and marketing of the identified natural substances. As a new technology
partner, the Lübeck-based Fraunhofer Research Institution for Marine
Biotechnology further strengthens the NatLifE 2020 team."
As scheduled, Phase 2 will start on March 01, 2016 and ends on February 28,
2019. The content of Phase 3, also planned for three years, will be
presented to the expert panel by the end of 2018.
About BRAIN
BRAIN AG is one of Europe's technology leaders in the field of industrial
'white' biotechnology. Within strategic alliances, BRAIN AG has identified
and developed numerous innovative products and solutions for companies in
the chemical, pharmaceutical, cosmetic and food industries by harnessing
nature's untapped biodiversity. These active product components are
identified by BRAIN AG and contained in the company's "BioArchive", one of
the most comprehensive archives of its kind. Since its foundation in 1993,
BRAIN has entered into 102 strategic cooperations with nearly every
prominent company in the chemical industry. Cooperation partners include
BASF, Bayer Schering, Clariant, DSM, Evonik Degussa, Henkel, Nutrinova,
RWE, Sandoz, Südzucker and Symrise. The company currently employs around
120 highly skilled personnel.
www.brain-biotech.de
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de
About NatLifE 2020
The NatLifE 2020 strategic alliance currently unites 22 industrial, SME and
academic partners. The alliance with the funding code FKZ 031A206 is
scheduled to last for nine years and has a total budget of Euro 30m. After
winning the bid, the alliance was the first strategic alliance to be
co-funded from February 01, 2013 under the German Ministry of Education and
Research's "Innovation Initiative for Industrial Biotechnology" programme.
The alliance's efforts are coordinated by BRAIN AG of Zwingenberg. Phase 2,
the development phase of the alliance, will last for three years and will
start as planned on March 01, 2016.
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any
forward-looking statements.
---------------------------------------------------------------------------
2016-03-01 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service